Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Catalyst Pharmaceuticals Community
NasdaqCM:CPRX Community
1
Narratives
written by author
0
Comments
on narratives written by author
87
Fair Values set
on narratives written by author
Community Investing Ideas
Catalyst Pharmaceuticals
Popular
Undervalued
Overvalued
Catalyst Pharmaceuticals
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts
Updated NCCN Guidelines Will Expand Rare Disease Diagnosis
Key Takeaways Expansion of diagnoses and payer coverage is driving broader patient access and sustained high revenue growth across Catalyst's rare disease portfolio. Strong product launches, durable margins, and disciplined business development position Catalyst for continued earnings growth amid increasing competition.
View narrative
US$34.29
FV
41.0% undervalued
intrinsic discount
8.09%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
42
users have followed this narrative
3 days ago
author updated this narrative
Your Valuation for
CPRX
CPRX
Catalyst Pharmaceuticals
Your Fair Value
US$
Current Price
US$20.23
2.9% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-21m
857m
2015
2018
2021
2024
2025
2027
2030
Revenue US$857.3m
Earnings US$320.3m
Advanced
Set Fair Value